137 results about "Gestational diabetes" patented technology

The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and / or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and / or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

The invention provides a synthetic polypeptide of Formula I′:or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and / or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

New uses for phenylketone carboxylate compounds and substituted aromatic compounds of Formula I, Formula I, IA, IB and IC, and their pharmaceutical acceptable salts are described for prevention or treatment of diabetes or a diabetes-related disorder in a subject in need thereof. Diabetes and diabetes-related disorder include Type I diabetes, Type II diabetes, maturity-onset diabetes of the young, latent autoimmune diabetes of adults (LADA), gestational diabetes, diabetic nephropathy, proteinuria, ketonuria, obesity, hyperglycemia, glucose intolerance, insulin resistance, hyperinsulinemia, hypercholesterolemia, hypertension, hyperlipoproteinemia, hyperlipidemia, hypertriglyceridemia, dyslipidemia, metabolic syndrome, syndrome X, diabetic neuropathy, diabetic retinopathy, hypoglycemia, cardiovascular disease, atherosclerosis, diabetic kidney disease, ketoacidosis, thrombotic disorders, sexual dysfunction, dermatopathy, edema, metabolic syndrome and renal disorders. The related pharmaceutical compositions and methods are also described. These compounds can be used in combination with comprising a therapeutic agent for lowering or controlling blood glucose level such as metformin or a thiazolidinedione.

The invention provides a synthetic polypeptide of Formula I′:or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

A device is described which provides an automated or manual means to perform chromatographic affinity-based A1c analyses of whole blood or hemolysates in less than 1 minute. Further, such applications are useful for the quantitation of glycated plasma proteins used in analysis of gestational diabetes. The device includes several modules integrated to accomplish processing and analysis of the blood sample. One such module includes a disposable liquid chromatographic column which may be rapidly packed and is easily assembled from readily available materials. Such columns and assemblies may be used in fluid chromatography applications requiring separations of complex materials for purposes of purification and / or quantitation of particular analytes. The columns may be used as stand-alone units or may be integrated into commercially available chromatography systems. The columns have a chemical composition and particle size that allow for low operational pressures.

The Present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and / or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the compounds of Formula (I) or (II), or compositions thereof, for treating or preventing a wide range of diseases (e.g., proliferative diseases (e.g., cancers, benign neoplasms, angiogenesis, inflammatory diseases, autoimmune diseases) and metabolic diseases (e.g., diabetes (e.g., type 2 diabetes, gestational diabetes)) in a subject. Treatment of a subject with a disease using a compound of Formula (I) or (II), or compositions thereof, may downregulate the expression and / or inhibit the activity of a kinase (e.g., a tyrosine kinase, such as a Tec kinase, in particular, bone marrow on X chromosome kinase (BMX)), and therefore, suppress tyrosine kinase singling in the subject.

The invention discloses an LC / MS (liquid chromatography-mass spectrometer) metabonomics analysis method based on serum of a GDM (gestational diabetes mellitus) patient. The method comprises the steps as follows: serum samples of a normal pregnant woman and a pregnant woman with GDM are collected, processed and separated by a chromatographic column, and mass spectrometric detection analysis is adopted; original data of an instrument is extracted and aligned after LC / MS detection analysis, and data free of noise disturbance and capable of being used for statistical analysis is obtained; and a multi-dimensional statistical model is established and visually displays metabolic profiling difference between the two groups, so that differential metabolites of the two groups are obtained, and the substances are subjected to preliminary evaluation. With the adoption of the method, the variation condition of the metabolites of the GDM patient can be presented comprehensively and synthetically, and the method can be used for providing powerful technical support for early diagnosis and prognosis of GDM.

The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and / or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

The invention relates to a special clinical nutrient composition for gestational diabetes and a preparation method of the nutrient composition. The composition comprises 20-35 parts of protein, 8-15 parts of fat, 25-40 parts of carbohydrate, 3-8 parts of dietary fiber, 0.6-1.2 parts of macroelements, 0.01-0.03 parts of microelements, 0.005-0.015 parts of fat-soluble vitamins, 0.08-0.2 parts of water-soluble vitamins, 0.05-0.6 parts of dietary essence, 0.5-4 parts of medicinal and edible components, 0.1-1 part of natural plant compounds and 0.1-0.4 parts of new resource food, wherein the medicinal and edible components are selected from at least one of Chinese yams, black sesame, radix puerariae, rhizoma polygonate, folium mori, fructus lycii, radix platycodonis and lilies; powder is prepared from the components in advance, and grease powder is prepared from fat with a microencapsulating technology. Through sieving and proportioning of the components, the nutrient composition can provide comprehensive nutrition for patients suffering from gestational diabetes, and digestion and absorption are facilitated; besides, the components with the blood glucose reducing function are added to assist in reducing the blood glucose level of the gestational diabetes and the disease risk, and growth demands and normal development of fetuses are guaranteed.

Disclosed are methods of producing a blunted postprandial glycemic response in an individual, and / or reducing postprandial insulin secretion, said methods comprising administering to the individual a nutritional or other product comprising gamma-cyclodextrin. Also disclosed are similar other methods directed toward the use of such products to provide weight and appetite control, to normalize blood glucose levels in individuals with impaired glucose tolerance, to minimize nighttime hypoglycemia in diabetic and non-diabetic patients, to prevent reactive hypoglycemia in susceptible non-diabetics, to normalize blood glucose levels in individuals with gestational diabetes or impaired glucose tolerance during gestation, and / or to provide a prolonged glycemic response during exercise. The methods are based upon the discovery that gamma-cyclodextrins are rapidly metabolized and absorbed in the small intestine, but subsequently result in a surprisingly blunted postprandial glycemic response and reduced insulin secretion.

The invention discloses a serum / blood plasma polypeptide marker related to gestational diabetes mellitus auxiliary early diagnosis and application thereof. The serum / blood plasma polypeptide marker ischaracterized in that the marker is selected from arbitrary one or more polypeptides of Q6PFW1, P35658, P32004 and Q9Y4H2. The serum / blood plasma polypeptide marker serving as a detection target is applied to preparation of gestational diabetes mellitus auxiliary early diagnosis reagents. The expression quantity of the marker for detecting pregnancy serum / blood plasma can be used in GDM auxiliaryearly diagnosis. Support is provided to clinical doctors for accurately predicting the GDM pathogenesis outcome of pregnancy and timely adopting personal prevention and treatment schemes, so that theoccurrence rate of GDM can be furthest reduced, and adverse pregnancy outcomes can be reduced.

Methods for treating gestational diabetes which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that lower blood glucose levels.

Methods for modulating diabetes, impaired glucose tolerance, gestational diabetes and glucose resistance in a mammal, particularly a human. In one embodiment the method comprises administering a gallotannin composition to a mammal in need of the same. The gallotannin composition comprises one or more select hydrolysable gallotannins. In another embodiment the method comprises administering a gallotannin variant composition comprising one ore more select gallotannin variant compounds to the subject. Methods of preventing or treating weight gain in a subject. The method comprises administering the gallotannin composition of the present invention, the gallotannin variant composition of the present invention, or a combination of the gallotannin composition of the present invention and the gallotannin variant composition of the present invention to the subject. The present invention also relates a gallotannin variant compound or a salt thereof, and a pharmaceutical composition comprising such compound or the salt thereof.

The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and / or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

The invention provides a bioconjugates comprising a synthetic polypeptide of Formula I′ (SEQ ID NO: 1):or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein and a half-life extending moiety wherein the peptide and the half-life extending moiety are covalently linked or fuse, optionally via a linker. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the bioconjugates of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Methods for treating gestational diabetes which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that lower blood glucose levels.

The present invention generally relates to novel GIP analogs and GIP hybrid polypeptides with selectable properties, which are useful as agents for the treatment and prevention of metabolic diseases and disorders, such as by controlling blood glucose levels, insulin levels and / or insulin secretion, inotropic effects, reduction of catabolic effects, slowing of gastric emptying to alleviate those. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin resistance, obesity, and diabetes of any kind, including type 1, type 2, and gestational diabetes.

The invention discloses a system and a method for predicting gestational diabetes mellitus, and relates to gestational diabetes mellitus. The system comprises: a data acquisition module for acquiringclinical indexes and clinical diagnosis results; a first index extraction module used for extracting and obtaining associated clinical indexes; a second index extraction module used for randomly combining the associated clinical indexes and calculating a combination with the highest correlation coefficient as an effective clinical index; a training module comprising a logistic regression model, asupport vector machine model, a K nearest neighbor classification model and a deep neural network model which are obtained through training according to effective clinical indexes; and a prediction module used for respectively inputting the effective clinical indexes of a pregnant woman to be predicted into the four models to obtain corresponding prediction results, and predicting the prediction results to obtain the onset risk of the pregnant woman to be predicted. The system and the method have the following beneficial effect that a pregnant woman can conveniently take preventive or interventional measures in advance by predicting the onset risk of gestational diabetes mellitus.

The use of probiotic bacteria in the manufacture of a composition for administration to a woman in at least the third trimester of pregnancy for prevention of gestational diabetes, normalising plasma glucose concentration and / or increasing insulin sensitivity.

The invention provides a synthetic polypeptide of Formula I′:or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Methods and spectra for monitoring fetal growth and predicting birth weight of an infant prior to birth are provided wherein one or more selected biological markers are measured in a sample of amniotic fluid obtained from a pregnant woman. Levels of the selected biochemical markers and / or spectra correlate with one or more medical conditions, such as fetal growth and birth weight of the infant, and gestational diabetes. A measurement probe for in situ measurement can be used safely and repeatedly. Monitoring and / or treatment of maternal and fetal health is also provided.

The invention provides a gestational diabetes mellitus screening method based on machine learning and physical examination data, and the method is applied in the technical field of disease screening.The method includes the following steps that first physical examination data is acquired and pretreated to obtain test samples; a target model obtained by the gestational diabetes mellitus screening method based on machine learning and physical examination data serves as a training mode for training the obtained test samples and outputting a predict result, when the predict result shows 1, it means that a pregnant suffers from gestational diabetes mellitus, and when the predict result is 0, it means that the pregnant does not suffer from gestational diabetes mellitus. According to the embodiment, a gestational diabetes mellitus screening model suitable for practical application scenarios is constructed via the LightGBM algorithm based technology and the characteristics of health data. Themodel can predict whether the pregnant suffers from gestational diabetes mellitus according to the genetic data and physical examination indexes of the pregnant, thus assisting doctors in diagnosis and treatment, and provides solutions for intelligent medical treatment. The purpose of improving the utilization rate of public medical resources is achieved.

A serum-based biomarker for diagnosing gestational diabetes, preeclampsia and fetal growth restriction (GDM-PREEC-FGR), based on retinoid profiling, and a method for diagnosing GDM-PREEC-FGR that specifically uses a blood sample to identify and measure the concentrations of retinol (vitamin A alcohol), retinyl esters and retinoic acid.

The invention provides a cyclic polypeptide of Formula I (SEQ ID NO: 1):X1-R-X3-X4-L-S-X7-X8-X9-X10-X11-X12-X13  Ior an amide, an ester or a salt thereof, or a bioconjugate thereof, wherein X1, X3, X4, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention or bioconjugates thereof, and their therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

The invention provides an early prediction marker for gestational diabetes mellitus and a detection method thereof. The marker is serum differential protein which comprises 33 proteins including fat plasma membrane related protein, antithrombin-III, apolipoprotein A5, apolipoprotein E and the like; the concentration change of the serum differential protein is detected by one or more of a high-throughput proteomics method, an enzyme linked immunosorbent assay technology and a protein chip technology so as to predict whether a to-be-detected object in the 12th-16th week of pregnancy is to suffer from gestational diabetes mellitus in the 24th-28th weeks of pregnancy; the prediction accuracy of the marker is high; and the detection method is simple to operate and can assist in early diagnosis of potential patients suffering from gestational diabetes mellitus so as to avoid adverse impacts of the disease on the health of patients and fetuses thereof.